Charles River Laboratories International, Inc. (CRL) earnings on August 5, 2026
More Charles River Laboratories International, Inc. earnings
Prior outlook: Optimistic Outcome: Accurate
Charles River Laboratories' stock surged after its earnings report, hitting an intraday high of 14.5% and closing up 11.1%. The jump came as the company noted a rebound in biotech demand and strong order activity.
CRL price around the earnings
260.72
Change: +11.4%
2026-08-05, 20:00 UTC
End of the measured window
233.97
244.65
255.32
266.00
233.97
August 5, 2026
- Price: green if it ends above the starting price; red if it ends below
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
- Results released
Pre-release: Strong historical beat rate, but analyst target implies slight downside with mixed trend strength.
Context analyzed before publication
- Trend
- Initial positive trend strength faded, leading to a weak positive trajectory into earnings.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.81
- Analysts covering the stock
- 14
- Average price target
- 228.5
- Lowest price target
- 135
- Highest price target
- 264
- Upside to price target
- -2.4%
- Revenue growth
- 1.2%
- Forward EPS
- 12.38
- Trailing EPS
- -3.77
- Analyst moves in the last 60 days
- 4
- Strong buy: 3
- Buy: 9
- Hold: 3
- Sell: 1
- Strong sell: 0
- Strong buy
- 3
- Buy
- 9
- Hold
- 3
- Sell
- 1
- Strong sell
- 0
- July 20, 2026 · CLSA: Downgrades rating (Outperform → Hold)
- July 13, 2026 · Mizuho: Maintains rating (Neutral → Neutral)
- July 9, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- June 17, 2026 · Morgan Stanley: Upgrades rating (Equal-Weight → Overweight)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (2)
- Mizuho Maintains Neutral on Charles River, Raises Price Target to $230 (opens in a new tab) — Benzinga
- Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $260 (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 233.97
- Average true range (ATR)
- 3.4%
- Distance to 52-week high
- -2.6%
- 14-day change (14d)
- +6.7%
- 30-day change (33d)
- +1.4%
- 30-day relative strength
- -2.1%
- SPY change (33d)
- +3.5%
- Nearest support
- 233.15
- Distance to nearest support
- 0.4%
- Nearest resistance
- 235.32
- Distance to nearest resistance
- 0.6%
- Volume accumulation ratio (14d / 46d)
- 1
- Mid: 233.15 (0.4% away, 0.1 ATR, 13 touches)
- Mid: 230.57 (1.5% away, 0.43 ATR, 14 touches)
- Minor: 227.58 (2.7% away, 0.8 ATR, 9 touches)
- Mid: 235.32 (0.6% away, 0.17 ATR, 15 touches)
- Mid: 237.06 (1.3% away, 0.39 ATR, 10 touches)
- Mid: 239.33 (2.3% away, 0.67 ATR, 2 touches)
Trends
Evidence
- Average earnings surprise
- +8.4%
- May 7, 2026: actual EPS 2.06 vs estimate 1.95 (surprise +5.4%)
- February 18, 2026: actual EPS 2.39 vs estimate 2.35 (surprise +1.9%)
- November 5, 2025: actual EPS 2.43 vs estimate 2.34 (surprise +3.9%)
- August 6, 2025: actual EPS 3.12 vs estimate 2.55 (surprise +22.4%)
Expected move
- Implied move
- +4.0%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 5.3%
- 75th percentile move
- 10.2%
- 90th percentile move
- 12.7%
- Up / down moves
- 10 / 10
- Average up move
- +6.8%
- Average down move
- -6.6%
Monitoring and close
What Charles River Laboratories International, Inc. reported
- Status
- Finished
| Actual EPS | 3.02 |
|---|---|
| EPS estimate | 2.74 |
| EPS surprise | +10.2% |
| Revenue | $1,004 million |
| Revenue estimate | $976 million |
| Revenue surprise | +2.9% |
Charles River held its Q2 2026 earnings call, following its beat and raised annual guidance.
Sources (17)
- Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High (opens in a new tab) — Benzinga
- CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market (opens in a new tab) — Zacks
- Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Charles River Laboratories Exec Says Continue To Expect Lower Volumes For Research Models In North America, Spending From Academic And Government Clients Has Been Constrained By Flat NIH Budgets And Slower Grant Processing; Q3 Adj EPS Expected At $2.90 - $3; Well Positioned To Support Our Acquisition Strategy, We'd Love To Be Able To Add A Couple Additional Companies To Our Portfolio (opens in a new tab) — Benzinga
- Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year? (opens in a new tab) — Zacks
- Charles River Blows Out Of A Buy Zone After One Metric Hits A Four-Year High (opens in a new tab) — Investor's Business Daily
- Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) — Zacks
- Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates (opens in a new tab) — Zacks
- Charles River Laboratories (NYSE:CRL) Tops Q2 Estimates and Raises Full-Year Outlook (opens in a new tab) — ChartMill
- Charles River Laboratories’s (NYSE:CRL) Q2 CY2026 Sales Top Estimates, Stock Soars (opens in a new tab) — StockStory
- Charles River Lowers FY2026 GAAP EPS Guidance from $5.35-$5.85 to $3.05-$3.35 vs $6.24 Est (opens in a new tab) — Benzinga
- Charles River Raises FY2026 Adj EPS Guidance from $10.80-$11.30 to $11.15-$11.45 vs $11.12 Est; Raises FY2026 Sales Guidance from $3.794B-$3.854B to $3.879B-$3.920B vs $3.850B Est (opens in a new tab) — Benzinga
- Charles River beat expectations in Q2: adjusted EPS of $3.02 versus $2.74 estimated, and revenue of $1.004B versus $975.687M expected. — Benzinga
- Charles River Q2 Adj. EPS $3.02 Beats $2.74 Estimate, Sales $1.004B Beat $975.687M Estimate (opens in a new tab) — Benzinga
- Charles River Laboratories Announces Second-Quarter 2026 Results (opens in a new tab) — Yahoo
- Charles River: Near-Term Inflection But Long-Term Risk (opens in a new tab) — SeekingAlpha
- Charles River Laboratories International, Inc. 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +8.1% pre-market, a move above the stock's usual reaction (about 5%). The figures confirm the optimistic scenario. In the 1,059 similar cases in our market history, the close held that direction 96% of the time.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +11.1%
- Max favorable move (MFE)
- 14.5%
- Max adverse move (MAE)
- 0%